KR102427192B1 - 항-인간 4-1bb 항체 및 그의 용도 - Google Patents

항-인간 4-1bb 항체 및 그의 용도 Download PDF

Info

Publication number
KR102427192B1
KR102427192B1 KR1020207006944A KR20207006944A KR102427192B1 KR 102427192 B1 KR102427192 B1 KR 102427192B1 KR 1020207006944 A KR1020207006944 A KR 1020207006944A KR 20207006944 A KR20207006944 A KR 20207006944A KR 102427192 B1 KR102427192 B1 KR 102427192B1
Authority
KR
South Korea
Prior art keywords
antibody
cancer
sequence
seq
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207006944A
Other languages
English (en)
Korean (ko)
Other versions
KR20200029618A (ko
Inventor
병 에스. 권
승-주 이
영 호 김
호-식 오
중 원 이
Original Assignee
주식회사 유틸렉스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 유틸렉스 filed Critical 주식회사 유틸렉스
Publication of KR20200029618A publication Critical patent/KR20200029618A/ko
Application granted granted Critical
Publication of KR102427192B1 publication Critical patent/KR102427192B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020207006944A 2017-01-06 2018-01-05 항-인간 4-1bb 항체 및 그의 용도 Active KR102427192B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762443281P 2017-01-06 2017-01-06
US62/443,281 2017-01-06
PCT/IB2018/000043 WO2018127787A1 (en) 2017-01-06 2018-01-05 Anti-human 4-1 bb antibodies and use thereof
KR1020197015730A KR102089072B1 (ko) 2017-01-06 2018-01-05 항-인간 4-1bb 항체 및 그의 용도

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020197015730A Division KR102089072B1 (ko) 2017-01-06 2018-01-05 항-인간 4-1bb 항체 및 그의 용도

Publications (2)

Publication Number Publication Date
KR20200029618A KR20200029618A (ko) 2020-03-18
KR102427192B1 true KR102427192B1 (ko) 2022-07-29

Family

ID=62791389

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020207006944A Active KR102427192B1 (ko) 2017-01-06 2018-01-05 항-인간 4-1bb 항체 및 그의 용도
KR1020197015730A Active KR102089072B1 (ko) 2017-01-06 2018-01-05 항-인간 4-1bb 항체 및 그의 용도

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020197015730A Active KR102089072B1 (ko) 2017-01-06 2018-01-05 항-인간 4-1bb 항체 및 그의 용도

Country Status (13)

Country Link
US (4) US10174122B2 (https=)
EP (2) EP4032911A1 (https=)
JP (2) JP6609724B1 (https=)
KR (2) KR102427192B1 (https=)
CN (2) CN112210010B (https=)
AU (3) AU2018206015B2 (https=)
BR (1) BR112019007714B1 (https=)
CA (1) CA3039772C (https=)
ES (1) ES2905890T3 (https=)
MX (1) MX374810B (https=)
RU (1) RU2725811C1 (https=)
SG (2) SG10201914064QA (https=)
WO (1) WO2018127787A1 (https=)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101503341B1 (ko) 2014-03-12 2015-03-18 국립암센터 자가암항원 특이적 cd8+ t 세포의 분리 및 증식방법
US10174122B2 (en) * 2017-01-06 2019-01-08 Eutilex Co., Ltd. Anti-human 4-1BB antibodies and uses thereof
JP7297672B2 (ja) 2017-04-13 2023-06-26 アジェナス インコーポレイテッド 抗ｃｄ１３７抗体およびその使用方法
SG11201913137VA (en) 2017-07-11 2020-01-30 Compass Therapeutics Llc Agonist antibodies that bind human cd137 and uses thereof
CN111511762B (zh) 2017-08-21 2025-05-06 天演药业公司 抗cd137分子及其用途
WO2019089753A2 (en) 2017-10-31 2019-05-09 Compass Therapeutics Llc Cd137 antibodies and pd-1 antagonists and uses thereof
US11851497B2 (en) 2017-11-20 2023-12-26 Compass Therapeutics Llc CD137 antibodies and tumor antigen-targeting antibodies and uses thereof
WO2019148445A1 (en) 2018-02-02 2019-08-08 Adagene Inc. Precision/context-dependent activatable antibodies, and methods of making and using the same
AU2019312200B2 (en) 2018-07-23 2024-11-14 Heidelberg Pharma Research Gmbh Use of anti-CD137 antibody drug conjugate (ADC) in allogeneic cell therapy
EP3835321A4 (en) 2018-08-10 2022-11-02 Chugai Seiyaku Kabushiki Kaisha ANTI-CD137 ANTIGEN-BINDING MOLECULE AND USE THEREOF
CA3110006A1 (en) * 2018-09-12 2020-03-19 Eucure (Beijing) Biopharma Co., Ltd Anti-tnfrsf9 antibodies and uses thereof
WO2020077635A1 (zh) 2018-10-19 2020-04-23 苏州丁孚靶点生物技术有限公司 抗cd137抗体及其应用
CN113286825B (zh) * 2018-11-30 2024-06-18 爱必乐生物公司 抗pd-l1/抗4-1bb双特异性抗体及其用途
JP7558534B2 (ja) * 2019-01-02 2024-10-01 キューエルエスエフ バイオセラピューティック インコーポレイテッド Ｃｄ１３７アゴニスト性抗体とその使用
SG11202110287QA (en) 2019-04-24 2021-10-28 Heidelberg Pharma Res Gmbh Amatoxin antibody-drug conjugates and uses thereof
CN118526580A (zh) * 2019-06-21 2024-08-23 瑞泽恩制药公司 结合psma和cd3的双特异性抗原结合分子与4-1bb共刺激组合的用途
WO2021132746A1 (en) * 2019-12-24 2021-07-01 Abl Bio, Inc. Anti-bcma/anti-4-1bb bispecific antibodies and uses thereof
JP7813704B2 (ja) 2019-12-10 2026-02-13 エービーエル バイオ インコーポレイテッド 抗ｂｃｍａ／抗４－１ｂｂ二重特異性抗体及びその用途
CN113045657B (zh) * 2019-12-26 2022-06-07 杭州济元基因科技有限公司 一种人源化抗人bcma单克隆抗体及其car-t细胞
TWI895351B (zh) * 2020-02-12 2025-09-01 日商中外製藥股份有限公司 用於癌症之治療的抗cd137抗原結合分子
AU2021225920A1 (en) * 2020-02-28 2022-09-15 Shanghai Henlius Biotech, Inc. Anti-CD137 construct and use thereof
CN115776989A (zh) * 2020-03-13 2023-03-10 尤利乌斯·马克西米利安维尔茨堡大学 靶向ror2的亲和力成熟和人源化结合结构域
KR20230012559A (ko) 2020-05-19 2023-01-26 베링거 인겔하임 인터내셔날 게엠베하 암 치료를 위한 결합 분자
WO2021251459A1 (ja) * 2020-06-11 2021-12-16 国立大学法人高知大学 ヒト化抗ｇｐｃ－１抗体
KR20230042524A (ko) * 2020-08-07 2023-03-28 주식회사 유틸렉스 항-her2 / 항-4-1bb 이중특이적 항체 및 이의 용도
CN114075287B (zh) 2020-08-18 2023-07-21 湖南远泰生物技术有限公司 人源化bcma抗体和bcma-car-t细胞
WO2022053864A1 (en) * 2020-09-08 2022-03-17 Kwon Byoung S Pd-1 polypeptide variants
CN114195894B (zh) * 2020-09-17 2025-02-25 普米斯生物技术(珠海)有限公司 一种靶向4-1bb的抗体及其应用
EP4276111A4 (en) * 2021-01-08 2025-04-30 Beijing Hanmi Pharmaceutical Co., Ltd. Antibody specifically binding to 4-1bb and antigen-binding fragment of antibody
CA3203718A1 (en) * 2021-01-08 2022-07-14 Jiawang Liu Anti-pd-l1/anti-4-1bb natural antibody structure-like heterodimeric form bispecific antibody and preparation thereof
EP4274852A4 (en) * 2021-01-11 2025-02-26 Eutilex Co., Ltd. BISPECIFIC EPITOP-BINDING PROTEIN WITH ANTI-4-1BB ANTIBODY AND PD-1 PROTEIN OR FRAGMENTS THEREOF AND USE THEREOF
JP2024530325A (ja) * 2021-08-31 2024-08-16 ラノバ メディシンズ リミテッド 抗４－１ｂｂナノボディ
WO2024040194A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
US12311033B2 (en) 2023-05-31 2025-05-27 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
WO2025076127A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025106539A1 (en) * 2023-11-14 2025-05-22 Mayo Foundation For Medical Education And Research Materials and methods for treating cancer
WO2025179294A2 (en) 2024-02-22 2025-08-28 Capstan Therapeutics, Inc. Immune engineering amplification
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7932045B2 (en) 2007-03-16 2011-04-26 University Of Ulsan Foundation For Industry Cooperation Method of isolating and proliferating autologous antigen-specific CD8+ T cell using anti-4-1BB antibodies
KR102089072B1 (ko) 2017-01-06 2020-03-17 주식회사 유틸렉스 항-인간 4-1bb 항체 및 그의 용도

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0359096B1 (en) 1988-09-15 1997-11-05 The Trustees Of Columbia University In The City Of New York Antibodies having modified carbohydrate content and methods of preparation and use
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
US5670356A (en) 1994-12-12 1997-09-23 Promega Corporation Modified luciferase
US5874304A (en) 1996-01-18 1999-02-23 University Of Florida Research Foundation, Inc. Humanized green fluorescent protein genes and methods
US6090381A (en) 1997-02-11 2000-07-18 Immunomedics, Inc. Stimulation of an immune response with antibodies labeled with the . .alpha-galactosyl epitope
WO1999024069A1 (fr) 1997-11-10 1999-05-20 Mochida Pharmaceutical Co., Ltd. Medicaments preventifs et therapeutiques pour des affections pulmonaires diffuses
ES2434961T5 (es) 1998-04-20 2018-01-18 Roche Glycart Ag Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo
US7030211B1 (en) 1998-07-08 2006-04-18 Gemvax As Antigenic peptides derived from telomerase
KR20000034847A (ko) * 1998-11-17 2000-06-26 성재갑 인간 4-1비비 분자에 대한 인간화 항체 및 이를 포함하는 약학조성물
EP1176195B1 (en) 1999-04-09 2013-05-22 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
CA2388245C (en) 1999-10-19 2012-01-10 Kyowa Kirin Co., Ltd. The use of serum-free adapted rat cells for producing heterologous polypeptides
AU1661201A (en) 1999-11-18 2001-05-30 Epimmune, Inc. Heteroclitic analogs and related methods
US20040146519A1 (en) 1999-12-10 2004-07-29 John Fikes Inducing cellular immune responses to carcinoembryonic antigen using peptide and nucleic acid compositions
SI1731912T1 (sl) 2000-08-21 2014-05-30 Apitope Technology (Bristol) Limited Postopek izbire peptida
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
CA2424977C (en) 2000-10-06 2008-03-18 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
ES2639222T5 (es) 2000-10-06 2023-11-24 Kyowa Kirin Co Ltd Células que producen unas composiciones de anticuerpo
KR100468321B1 (ko) 2001-02-08 2005-01-27 학교법인 울산공업학원 종양 및 에이즈치료용 폴리펩타이드
AU2002252268B2 (en) 2001-03-09 2007-01-18 Baylor Research Institute Method of treating malignancies through induction of blood immune responses
AU2002364935A1 (en) 2001-10-09 2003-06-23 Mayo Foundation For Medical Education And Research Enhancement of immune responses by 4-1bb-binding agents
HUP0600342A3 (en) 2001-10-25 2011-03-28 Genentech Inc Glycoprotein compositions
KR100500286B1 (ko) 2002-07-02 2005-07-11 현대모비스 주식회사 자동차용 램프 스위치 장치
WO2004016733A2 (en) 2002-08-16 2004-02-26 Agensys, Inc. Nucleic acid and corresponding protein entitled 251p5g2 useful in treatment and detection of cancer
KR100500283B1 (ko) 2003-03-25 2005-07-11 이뮤노믹스 주식회사 인간 4-1비비 분자에 대한 인간화 모노클로날 폴리펩티드 및 이를 포함하는 약학 조성물
EP1623017B1 (en) 2003-05-08 2010-09-15 Life Technologies Corporation Generation and isolation of antigen-specific t cells
US20050011582A1 (en) 2003-06-06 2005-01-20 Haug Jeffrey S. Fluid delivery system for a flow cytometer
US7288638B2 (en) * 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
AR046094A1 (es) * 2003-10-10 2005-11-23 Bristol Myers Squibb Co Anticuerpos completamente humanos contra 4-1bb humano
KR100694508B1 (ko) * 2005-05-24 2007-03-13 울산대학교 산학협력단 Ｈｂｂｋ４항체를 포함하는 암 질환 치료용 약학조성물및 이를 이용한 암의 면역치료 방법
CA2651328A1 (en) 2006-05-05 2007-11-15 Opexa Therapeutics T-cell vaccine
KR101103603B1 (ko) 2008-07-25 2012-01-09 국립암센터 4-1ｂｂｌ 펜타머 단백질을 이용한 항원 특이적 ｃｄ８＋ｔ 세포의 분리 및 증식 방법
PL2172211T3 (pl) 2008-10-01 2015-05-29 Immatics Biotechnologies Gmbh Kompozycja związanych z guzem peptydów i związana z tym szczepionka przeciwrakowa do leczenia glejaka (GBM) i innych rodzajów raka
KR20100043130A (ko) 2008-10-18 2010-04-28 울산대학교 산학협력단 세포 활성 조성물
US10817851B2 (en) 2009-12-23 2020-10-27 Aristocrat Technologies Australia Pty Limited System and method for cashless gaming
PT2614082T (pt) * 2010-09-09 2018-12-03 Pfizer Moléculas de ligação a 4-1bb
CA2861206C (en) 2012-01-13 2021-07-06 Richard J. O'reilly Immunogenic wt-1 peptides and methods of use thereof
EP3686219A1 (en) * 2014-02-04 2020-07-29 Pfizer Inc Combination of a pd-1 antagonist and a 4-1bb agonist for treating cancer
KR101503341B1 (ko) 2014-03-12 2015-03-18 국립암센터 자가암항원 특이적 cd8+ t 세포의 분리 및 증식방법
EP3144388B1 (en) * 2014-05-13 2020-07-01 Chugai Seiyaku Kabushiki Kaisha T cell-redirecting antigen-binding molecule for cells having immunosuppression function
AU2015264528A1 (en) * 2014-05-21 2016-11-03 Kyowa Hakko Kirin Co., Ltd. Combination of an anti-CCR4 antibody and a 4-1BB agonist for treating cancer
US20170247455A1 (en) * 2014-08-22 2017-08-31 Bristol-Myers Squibb Company Treatment of cancer using a combination of an anti-pd-1 antibody and an anti-cd137 antibody
TW201632559A (zh) * 2015-02-22 2016-09-16 索倫多醫療公司 結合ｃｄ１３７之抗體治療劑
PH12017501857B1 (en) * 2015-06-16 2024-01-17 Merck Patent Gmbh Pd-l1 antagonist combination treatments
EP3464362B1 (en) * 2016-05-27 2020-12-09 AbbVie Biotherapeutics Inc. Anti-4-1bb antibodies and their uses
GB201619648D0 (en) * 2016-11-21 2017-01-04 Alligator Bioscience Ab Novel antibodies and uses thereof
WO2019113557A1 (en) 2017-12-08 2019-06-13 Juno Therapeutics, Inc. Process for producing a composition of engineered t cells
JP2021533759A (ja) 2018-08-10 2021-12-09 ユーティレックス カンパニー リミテッド 癌抗原特異的ｃｄ８＋ｔ細胞を調製および凍結保存するための方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7932045B2 (en) 2007-03-16 2011-04-26 University Of Ulsan Foundation For Industry Cooperation Method of isolating and proliferating autologous antigen-specific CD8+ T cell using anti-4-1BB antibodies
KR102089072B1 (ko) 2017-01-06 2020-03-17 주식회사 유틸렉스 항-인간 4-1bb 항체 및 그의 용도

Also Published As

Publication number Publication date
RU2725811C1 (ru) 2020-07-06
AU2019204847A1 (en) 2019-08-01
US10774151B2 (en) 2020-09-15
EP4032911A1 (en) 2022-07-27
WO2018127787A1 (en) 2018-07-12
KR102089072B1 (ko) 2020-03-17
SG11201903021WA (en) 2019-05-30
KR20190095919A (ko) 2019-08-16
JP6609724B1 (ja) 2019-11-20
CN112210010A (zh) 2021-01-12
JP2020503245A (ja) 2020-01-30
US20210214455A1 (en) 2021-07-15
RU2020120077A (ru) 2020-12-03
US10919972B2 (en) 2021-02-16
BR112019007714A2 (pt) 2019-07-09
BR112019007714B1 (pt) 2022-01-18
NZ753036A (en) 2020-10-30
US20180258177A1 (en) 2018-09-13
KR20200029618A (ko) 2020-03-18
RU2020120077A3 (https=) 2022-02-04
US10174122B2 (en) 2019-01-08
EP3523332B1 (en) 2021-12-29
ES2905890T3 (es) 2022-04-12
US11859004B2 (en) 2024-01-02
AU2021202474A1 (en) 2021-05-20
CN110392696A (zh) 2019-10-29
AU2019204847B2 (en) 2021-05-20
CA3039772A1 (en) 2018-07-12
CA3039772C (en) 2020-08-25
MX2019004692A (es) 2019-11-08
CN110392696B (zh) 2020-09-11
US20190071510A1 (en) 2019-03-07
JP7153626B2 (ja) 2022-10-14
MX374810B (es) 2025-03-06
JP2020036595A (ja) 2020-03-12
US20200172626A1 (en) 2020-06-04
AU2018206015B2 (en) 2019-05-30
CN112210010B (zh) 2023-12-05
AU2018206015A1 (en) 2019-05-16
SG10201914064QA (en) 2020-03-30
EP3523332A1 (en) 2019-08-14
EP3523332A4 (en) 2019-10-09

Similar Documents

Publication Publication Date Title
US11859004B2 (en) Anti-human 4-1BB antibodies and uses thereof
US20210277139A1 (en) Ifn-gamma-inducible regulatory t cell convertible anti-cancer (irtca) antibody and uses thereof
RU2777573C2 (ru) Антитела против 4-1bb человека и их применение
HK40006081B (en) Anti-human 4-1 bb antibodies and use thereof
HK40006081A (en) Anti-human 4-1 bb antibodies and use thereof
HK40016571A (en) Anti-human 4-1 bb antibodies and use thereof
HK40016571B (en) Anti-human 4-1 bb antibodies and use thereof
NZ753036B2 (en) Anti-human 4-1 bb antibodies and use thereof

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20200309

Application number text: 1020197015730

Filing date: 20190531

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210105

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20220126

Patent event code: PE09021S01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20220420

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20220704

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20220726

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20220726

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20250624

Start annual number: 4

End annual number: 4